Last reviewed · How we verify
NCT04032600: ATLANTIS
Malignant Ascites in Ovarian Cancer: Impact of Total Paracentesis on Hemodynamics
NA trial testing Paracentesis in Malignant Ascites in 61 participants. Completed in 9 September 2019.
9 August 2019
Quick facts
| Lead sponsor | Charite University, Berlin, Germany |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 61 |
| Start date | 1 August 2017 |
| Primary completion | 9 August 2019 |
| Estimated completion | 9 September 2019 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Paracentesis — full drug profile →
Conditions studied
- Malignant Ascites — all drugs for Malignant Ascites →
- Ovarian Cancer — all drugs for Ovarian Cancer →
- Hemodynamic Instability — all drugs for Hemodynamic Instability →
Sponsor
Charite University, Berlin, Germany
Who can join
18 and older, female only, with Malignant Ascites or Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The ATLANTIS-study was designed to determine the safety of a full paracentesis in patients with malignant ascites due to ovarian cancer. The underlying hypothesis states, that full paracentesis does not impair safety, compared to fractioned paracentesis with clamping of the drain. Half of the patients will receive a full paracentesis, while the other half will receive fractioned paracentesis with clamping of the drain after 3 liters of ascites was evacuated. All patients receive extensive monitoring of hemodynamics and kidney function.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Management of drainage for malignant ascites in gynaecological cancer.
Kietpeerakool C, Rattanakanokchai S, Jampathong N, Srisomboon J, et al · · 2019 · cited 8× · PMID 31825525 · DOI 10.1002/14651858.cd007794.pub3
Verify or expand the search:
- PubMed search for NCT04032600
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Paracentesis
Trials testing the same drug.
- NCT05998135 — Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer · Phase 2 · recruiting
- NCT05220891 — Comparison of Crystalloid and Colloid I.V Fluid Therapy in Prevention of Paracentesis Induced Circulatory Dysfunction (P · unknown
- NCT04314401 — National Cancer Institute "Cancer Moonshot Biobank" · active not recruiting
Other recruiting trials for Malignant Ascites
Currently open trials in the same condition.
- NCT07397819 — Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor N · Phase 1, PHASE2 · recruiting
- NCT06432296 — Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody · Phase 3 · active not recruiting
- NCT06433869 — The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in th · Phase 2 · recruiting
- NCT04326946 — International Alfapump Cohort Study · active not recruiting
Other Charite University, Berlin, Germany trials
Trials by the same sponsor.
- NCT07486167 — Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congeni · Phase 1, PHASE2 · not yet recruiting
- NCT07476729 — International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) · Phase 3 · not yet recruiting
- NCT07503054 — Ovarian Cancer Screening and AI · NA · not yet recruiting
- NCT07529197 — Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS · recruiting
- NCT07388693 — Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04032600 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Charite University, Berlin, Germany
- Last refreshed: 8 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04032600.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing